Position in GSK
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$27,786,793
New position
Shares Held
530,080
first reported quarter
Ownership
0.026%
of shares outstanding
% of Portfolio
0.13%
of 13F equity value
Holder Rank
#59
of 1,033 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Life Cycle Investment Partners Ltd holds $545,754,539 across 7 Drug Manufacturers - General names. GSK ranks #7 (5.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
125,054 | $149,993,531 | |
| 2 | ABBV |
AbbVie Inc.
|
542,382 | $136,485,006 | |
| 3 | GILD |
Gilead Sciences, Inc.
|
521,552 | $65,892,879 | |
| 4 | JNJ |
Johnson & Johnson
|
248,443 | $63,097,068 | |
| 5 | AMGN |
Amgen Inc
|
151,355 | $54,808,672 | |
| 6 | MRK |
Merck & Co., Inc.
|
371,133 | $47,690,590 | |
| 7 | GSK |
GSK plc
This page
|
530,080 | $27,786,793 |
All Filings in GSK
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $27,786,793 | 530,080 | Shares | Sole | 2026-08-13 | |
| No filing history on record for this holder in this stock. | ||||||